RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema
China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...
September 2025
AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure
AstraZeneca plc (AZ; NASDAQ: AZN) has unveiled a plan to standardise its share‑listing structure across...
C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar
C‑MER Medical Holdings Limited (HKG: 3309) announced that its joint‑venture arm, Health Hope Pharma Limited...
NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs
The National Medical Products Administration (NMPA) has issued a new regulatory framework, titled “Announcement on...
MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint
MicroPort Scientific Corporation (HKG: 0853) disclosed that CRM Cayman, MicroPort CardioFlow Medtech Corporation, and MicroPort CardioFlow...
Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) disclosed that its subsidiary, Shanghai JunTop...
AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform
China‑based AccurEdit Therapeutics (Suzhou) Co., Ltd. announced that it has closed a US$75 million Series A financing...
Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection
China‑based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long‑acting recombinant human follicle‑stimulating hormone—CTP fusion...
Ipsen Launches BYLVAY in China for Rare Liver Disease
France‑based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the official commercial launch of its rare‑disease...
TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline
China‑based TJ Biopharma announced today the successful completion of a Series C2 financing round that raised...
Full‑Life Technologies Raises $77 M in Series C and Debt Funding
Full‑Life Technologies, a global radiotherapeutics integrator, announced today the successful completion of $77 million in financing,...
GSK Names Luke Miels as CEO to Drive Growth
GlaxoSmithKline (GSK; NYSE: GSK) announced that Luke Miels has been appointed CEO Designate and will...
Simnova Secures FDA IND for CAR‑NK Therapy in SLE
Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19‑targeted chimeric antigen receptor gene‑modified natural...
Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine
China’s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China...
Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First‑In‑Class Glucokinase Activator
China‑based Hua Medicine (HKG: 2552) announced that the Hong Kong Department of Health has accepted its...
Xinhua Pharma Wins China Trial Approval for Dual‑Mechanism PAH Drug LXH‑1211
Shandong Xinhua Pharmaceutical Co., Ltd. (HKG: 0719) announced that its pulmonary arterial hypertension (PAH) candidate...
Simcere Secures FDA Approval for ADC SIM0609 in Advanced Solid Tumors
Simcere Pharmaceutical Group Limited (HKG: 2096) announced that the U.S. Food and Drug Administration (FDA)...
CMS Wins NMPA Green Light for Phase‑3 Trial of MG‑K10 Anti‑IL‑4Rα in Chronic Urticaria
China Medical System Holdings Limited (CMS, HKG: 0867) announced that the National Medical Products Administration...
Eisai & Biogen Secure Leqembi China Maintenance Approval
Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced...
HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors
HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast‑growing Chinese biotech, announced that the National Medical Products...